Antireflux Surgery Versus Antireflux Medication and Risk of Esophageal Adenocarcinoma in Patients With Barrett’s Esophagus

Åkerström, Johan Hardvik; Santoni, Giola; von Euler Chelpin, My; Ness-Jensen, Eivind; Kauppila, Joonas H.; Holmberg, Dag; Lagergren, Jesper

doi:10.1053/j.gastro.2023.08.050

Gastroenterology

2024

DOI: 10.1053/j.gastro.2023.08.050

|View full text |Cite

Antireflux Surgery Versus Antireflux Medication and Risk of Esophageal Adenocarcinoma in Patients With Barrett’s Esophagus

Johan Hardvik Åkerström,

Giola Santoni,

My von Euler Chelpin

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article6

Relationship

Self Cite0

Independent6

Authors

Journals

Cited by 9 publications

(1 citation statement)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Upper digestive tract: Esophageal cancer has been directly related to reflux disease for decades, [7][8][9] and our contention is that many of these individuals have chronic inflammation as the principal cause of SIS. The same observation has been made for gastric cancer.…”

mentioning

confidence: 99%

Splanchnic inflammatory syndrome and the not-so-silent risk of cancer

Semelka MD,

Ramalho MD

2024

GHOA

View full text Add to dashboard Cite

mentioning

confidence: 99%

Splanchnic inflammatory syndrome and the not-so-silent risk of cancer

Semelka MD,

Ramalho MD

2024

GHOA

View full text Add to dashboard Cite

Current status and perspectives of esophageal cancer: a comprehensive review

Jiang,

Zhang,

et al. 2024

Cancer Communications

View full text Add to dashboard Cite

Esophageal cancer (EC) continues to be a significant global health concern, with two main subtypes: esophageal squamous cell carcinoma and esophageal adenocarcinoma. Prevention and changes in etiology, improvements in early detection, and refinements in the treatment have led to remarkable progress in the outcomes of EC patients in the past two decades. This seminar provides an in‐depth analysis of advances in the epidemiology, disease biology, screening, diagnosis, and treatment landscape of esophageal cancer, focusing on the ongoing debate surrounding multimodality therapy. Despite significant advancements, EC remains a deadly disease, underscoring the need for continued research into early detection methods, understanding the molecular mechanisms, and developing effective treatments.

show abstract

Verhindert eine Fundoplikatio das Barrett-Karzinom?

H. Waggershauser

2024

InFo Hämatol Onkol

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Antireflux Surgery Versus Antireflux Medication and Risk of Esophageal Adenocarcinoma in Patients With Barrett’s Esophagus

Cited by 9 publications

References 39 publications

Splanchnic inflammatory syndrome and the not-so-silent risk of cancer

Splanchnic inflammatory syndrome and the not-so-silent risk of cancer

Current status and perspectives of esophageal cancer: a comprehensive review

Verhindert eine Fundoplikatio das Barrett-Karzinom?

Contact Info

Product

Resources

About